DexCom (DXCM) Executive Chair Kevin Sayer Sells Shares

What Happened

• Kevin R. Sayer, Executive Chair and Director of DexCom (DXCM), sold a total of 26,756 shares in open‑market transactions on August 20, 2026 for aggregate proceeds of about $2,408,242.
  • 19,308 shares sold at a weighted average price of $89.71 — proceeds ~$1,732,043.
  • 7,351 shares sold at a weighted average price of $90.78 — proceeds ~$667,332.
  • 97 shares sold at $91.41 — proceeds ~$8,867.
• All sales were reported as dispositions (S) and were made pursuant to a pre-established 10b5-1 trading plan adopted February 18, 2026.

Key Details

• Transaction date: August 20, 2026; Form 4 filed August 24, 2026 (within the typical two-business-day filing window).
• Prices: listed as weighted averages; some trades were executed in multiple fills with reported price ranges of $89.275–$90.25 and $90.32–$91.19 (the filing says it will provide per-trade details on request).
• Total shares sold: 26,756; total proceeds: ≈ $2.41 million.
• Shares owned after transaction: not specified in the excerpt. The filing notes 106,972 unvested restricted stock units are included in reported holdings (32,749 granted 3/8/26; 56,993 granted 3/8/25; 17,230 granted 3/8/24) and vest on schedules through 2027–2028.
• Footnotes: sales were pursuant to a 10b5‑1 plan and the reporting person will supply detailed per-trade numbers/prices upon request.

Context

• These sales were made under a 10b5‑1 plan (a pre-scheduled, orderly disposition program). While insider purchases can be interpreted as stronger bullish signals, sales executed under 10b5‑1 plans are generally routine and follow pre-set instructions rather than necessarily reflecting a change in insider sentiment.